Statistical Analysis Of An International 10 Year Prospective Family Study Of Gene-environment Interactions On Risk Of Female Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$450,198.00
Summary
This study will provide new and credible information on how the effects of environmental and lifestyle factors on breast cancer risk depend on a woman's underlying genetic susceptibility using a large, international 10 year prospective family study.
Improving The Evaluation Of New Cancer Therapies To Expedite Patient Access
Funder
National Health and Medical Research Council
Funding Amount
$412,888.00
Summary
The government funds cancer drugs, but drugs have to provide value for money to Australian taxpayers. Most proposed cancer drugs provide a benefit to patients but reaching agreement on how much the government will pay for these drugs often delays access by months, and often over a year due to uncertainty regarding drugs’ long-term effects. This research will test methods and develop guidelines to reduce this uncertainty and provide earlier access to new cancer drugs.
Prognostic Significance Of Circulating Tumour Biomarkers In Patients Treated With Curative-intent Radiotherapy For NSCLC
Funder
National Health and Medical Research Council
Funding Amount
$877,098.00
Summary
More than 50% of cancer patients in Australia receive radiotherapy but many later die from distant metastases. This study of circulating biomarkers (tumour cells and DNA in the bloodstream) builds on evidence from research at Peter Mac showing that some lung cancers might spread during treatment with radiotherapy that would otherwise be curative. This study will help identify cancer patients at high risk of secondary cancers and could allow us to modify treatments to prevent them.
Risk Of Recurrence After Diagnosis Of Invasive Breast Cancer By Molecular Subtype As Defined By ER, PR And Her2 Status
Funder
National Health and Medical Research Council
Funding Amount
$500,622.00
Summary
Breast cancer is a heterogeneous disease. Molecular subtypes have been identified that differ in terms of prognosis and response to treatment. This study aims to estimate recurrence free survival of breast cancer by molecular subtypes in a population-based sample of Australian women. The results will assist clinicians to guide their therapeutic decisions and will inform women about their anticipated outcome after diagnosis of breast cancer.
Phase III Study Of The Impact Of A Physical Activity Program On Disease-free Survival For Early Colon Cancer
Funder
National Health and Medical Research Council
Funding Amount
$2,556,385.00
Summary
There is clear evidence that physical activity can reduce the risk of developing bowel cancer and some evidence suggesting it may decrease the risk of a recurrence of bowel cancer. This study will provide reliable evidence as to whether people who participate in a structured physical activity programme after treatment for stage II or III colorectal cancer can increase their likelihood of being alive without a cancer recurrence at three years, compared to those who have standard follow-up.
Can Pentoxifylline Improve Long-term Outcomes In Preterm Infants With Late-onset Sepsis Or Necrotizing Enterocolitis – A Pragmatic, Randomized, Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,901,130.00
Summary
Very preterm infants are at high risk of death and disability. Brain injury is often the result of inflammation caused by infection or bowel disease. To date, there is no treatment to reduce the harmful effects of inflammation. Pentoxifylline reduces inflammation and is a promising, safe and inexpensive treatment option for preterm infants. This study will determine whether Pentoxifylline in addition to antibiotics improves survival without disability in preterm infants.
Utilising Circulating Tumour DNA (ctDNA) To Optimise The Adjuvant Therapy And Follow-up Of Patients With Locally Advanced Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,316,682.00
Summary
The management of patients after surgery for rectal cancer presents multilpe dilemmas; what treatment should be given and to which patients? Our initial studies in colorectal cancer patients demonstrate that a novel blood biomarker (circulating tumour DNA) can accurately predict patient risk of recurrence and with serial samples, can indicate whether chemotherapy is being effective. During follow-up changes in this biomarker promise to be a specific and very early indicator of cancer recurrence.
Preclinical Development Of TLR Signalling Inhibitors For Prevention Of Preterm Labour And Fetal Inflammatory Injury
Funder
National Health and Medical Research Council
Funding Amount
$690,821.00
Summary
Preterm birth affects 8% of Australian births and is a major cause of infant and child health problems. Therapies to prevent or delay prematurity are urgently required. This study will investigate new drugs that suppress the triggers of preterm labour. We will evaluate drug effects in mice and human placental tissue, to demonstrate safety and fetal protection from inflammatory injury that occurs with prematurity. Successful completion of the study is expected to lead to clinical trials in women.
IMPROVE - Investigating Medication Re-Purposing To Reduce Risk Of OVarian Cancer And Extend Survival
Funder
National Health and Medical Research Council
Funding Amount
$430,196.00
Summary
Ovarian cancer is the 6th most common cause of cancer death in women and the proportion of women who die from their disease has not improved substantially over time. This large-scale study will use de-identified data from the Pharmaceutical Benefits Scheme, the Australian Cancer Database and the National Death Index to investigate whether medications commonly used for other conditions can help decrease the risk of ovarian cancer developing or improve survival from ovarian cancer after diagnosis.
Unravelling The Mechanism Coupling Synaptic Activity With Neurotrophin Signaling In The Nervous System
Funder
National Health and Medical Research Council
Funding Amount
$640,815.00
Summary
Although active brain cells are known to survive for much longer than inactive ones, the mechanism underpinning this essential process has remained elusive. We have uncovered a direct coupling between neuronal activity and survival signals. The purpose of this grant application is to establish the molecular mechanism underpinning this coupling and understand how neuropathic pathogens manage to harness it with devastating effects to the brain.